Thomas J. Brya
Nessuna posizione attualmente
Profilo
Thomas J.
Brya was the founder who founded GeneriCo LLC in 2013 and served as President & Chief Executive Officer.
He also held former positions as Chairman at Arch Oncology, Inc., Vice President & General Manager at Cardinal Health, Inc., Senior Vice President-Corporate Development at AMAG Pharma USA, Inc., Vice President at Global Therapeutics, Inc., and Senior Vice President-Business Development at ABIONYX Pharma SA. Mr. Brya's education history includes an undergraduate degree from Benedictine University in 1981, an MBA from Northwestern University in 2004, and a graduate degree from DePaul University in 1987.
Precedenti posizioni note di Thomas J. Brya
| Società | Posizione | Fine |
|---|---|---|
GeneriCo LLC
 GeneriCo LLC Pharmaceuticals: GenericHealth Technology GeneriCo LLC develops and markets generic drugs. The firm also has an embedded drug delivery technology, which used to make generic drugs to the targeted markets. Its products include pipeline and therapeutic areas. The company was founded by Thomas J. Brya, Michael Grimshaw, and Shu Zhu in 2013 and is headquartered in St. Louis, MO. | Amministratore Delegato | - |
| Global Therapeutics, Inc. | Corporate Officer/Principal | - |
AMAG Pharma USA, Inc.
 AMAG Pharma USA, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharma USA, Inc. engages in the provision of pharmaceutical products to independent pharmacies, managed care organizations, hospitals, pharmacy benefit management companies, government entities, and physicians. The company was founded by Victor M. Hermelin in 1942 and is headquartered in Waltham, MA. | Corporate Officer/Principal | - |
Arch Oncology, Inc.
 Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | Presidente | - |
| CARDINAL HEALTH, INC. | Corporate Officer/Principal | - |
Formazione di Thomas J. Brya
| Benedictine University | Undergraduate Degree |
| Northwestern University | Masters Business Admin |
| DePaul University | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| CARDINAL HEALTH, INC. | Distribution Services |
| ABIONYX PHARMA | Health Technology |
| Aziende private | 4 |
|---|---|
AMAG Pharma USA, Inc.
AMAG Pharma USA, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharma USA, Inc. engages in the provision of pharmaceutical products to independent pharmacies, managed care organizations, hospitals, pharmacy benefit management companies, government entities, and physicians. The company was founded by Victor M. Hermelin in 1942 and is headquartered in Waltham, MA. | Health Technology |
GeneriCo LLC
GeneriCo LLC Pharmaceuticals: GenericHealth Technology GeneriCo LLC develops and markets generic drugs. The firm also has an embedded drug delivery technology, which used to make generic drugs to the targeted markets. Its products include pipeline and therapeutic areas. The company was founded by Thomas J. Brya, Michael Grimshaw, and Shu Zhu in 2013 and is headquartered in St. Louis, MO. | Health Technology |
| Global Therapeutics, Inc. | Commercial Services |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | Commercial Services |
- Borsa valori
- Insiders
- Thomas J. Brya
